NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Appili Therapeutics Inc. (APLI.TO) Stock Analysis

Appili Therapeutics Inc. (APLI.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

APLI.TO

CA$0.01

CA$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APLI.TO with… →

APLI.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.01
Previous Close
CA$0.01
52-Week Range
0.01–0.04
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.19
Valuation
Market Cap
CA$1.32M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.03
Financials (FY)
Revenue (FY)
CA$244.18K+143.10%
Net Income (FY)
−CA$4.24M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
132.37M
1-Year Return
−33.33%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
29.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APLI.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.00%
2025−28.57%
2024+0.00%
2023−22.22%
2022−60.87%
2021−90.57%
2020+62.67%
2019 (partial year)−6.25%

As of September 4, 2026.

APLI.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$244.18K−CA$4.24M−1736.7%
2024CA$100.44K−CA$2.62M−2613.1%
2023CA$827.41K−CA$3.78M−457.0%
2022CA$334.18K−CA$9.24M−2765.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$244.18K—−CA$3.82M−CA$4.24M−1736.7%
2024CA$100.44K—−CA$190.84K−CA$2.62M−2613.1%
2023CA$827.41K—−CA$2.16M−CA$3.78M−457.0%
2022CA$334.18K—−CA$7.78M−CA$9.24M−2765.9%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

APLI.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPLI.TOBiotechnology medianvs median
P/S ratio3.6615.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Appili Therapeutics Inc. (APLI.TO) is capitalised at CA$1.32M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 7 employees.

Over the past 52 weeks the price has ranged from CA$0.01 to CA$0.04. APLI.TO last closed at CA$0.01 on September 4, 2026. The close was unchanged from the previous session.

Financial Health

Fiscal 2025 revenue came to CA$244.18K. That is +143.10% against the prior fiscal year, when revenue was CA$100.44K. The same year closed with a net loss of CA$4.24M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.03.

Across the 4 fiscal years on file, revenue moves from CA$334.18K in 2022 to CA$244.18K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3.66. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is −0.19. Daily returns over the trailing 7 years annualize to a volatility of 161.39%. Over the trailing twelve months the price has returned −33.33%. Across 5 years the annualized return works out at −59.06%.

Growth & Income

The record shows no dividend for APLI.TO.

2026 is still running; the price is −60.00% year to date. The strongest complete calendar year on file is 2020 at +62.67%; the weakest is 2021 at −90.57%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Appili Therapeutics Inc. (APLI.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Appili Therapeutics Inc. APLI.TO CA$1.32M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Appili Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Appili Therapeutics Inc.

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Visit website →